Recent Dermatology Advances: JAKs, Biologics, and Innovative Treatments

Conclusions

• Many recent dermatology studies point to more precise risk stratification and surveillance, especially for acral melanoma and stage II melanoma using anatomic site and tumor-infiltrating lymphocytes.
• Simple, low-cost interventions can be highly effective for common problems, as shown by saturated saline for plantar warts and improved nail outcomes with careful surgical technique and reconstruction.
• Nail surgery can often be less destructive than traditionally feared, with biopsy, matrix procedures, and even nail unit transplantation preserving or restoring function and appearance.
• Topical JAK inhibitors are emerging as meaningful options for conditions such as chronic hand eczema when systemic therapy is not tolerated.
• Inflammatory skin diseases often require broader assessment of the whole patient, because biologics can improve synovitis and enthesitis and chronic inflammation increases cardiovascular risk.
• New immunotherapies and targeted agents are improving outcomes in advanced skin cancer, including cutaneous squamous cell carcinoma and Merkel cell carcinoma.
• Rosacea appears to have distinct inflammatory and neurogenic endotypes, suggesting that different mechanisms may need different treatments.
• Antimicrobial photodynamic therapy may offer a useful rescue strategy for highly resistant fungal wound infections when antifungals fail.
• Biotin is not a harmless supplement and may cause dangerous laboratory test interference without clear benefit for most adults with hair or nail complaints.
• Ritlecitinib and other JAK-based approaches can produce meaningful responses in alopecia areata, with treatment response influenced by prior JAK exposure and body site.
• Calciphylaxis may be better understood as a thrombotic as well as calcific process, implying that clot-targeting therapy could matter.
• Some previously difficult diseases, including porokeratosis ptychotropica and CCCA, may respond better when treatment addresses both inflammation and fibrosis.
• CCCA likely behaves as a fibrosis-prone inflammatory disorder, so controlling associated pattern alopecia and using anti-fibrotic approaches such as metformin may improve outcomes.
• Hydroxychloroquine may help prevent progression of cutaneous lupus to systemic disease, supporting earlier treatment in selected patients.
• New topical therapies and procedural approaches are expanding options for hyperhidrosis, hidradenitis suppurativa, and other chronic inflammatory skin diseases.
• Evidence is accumulating that lower doses of some biologics and immunomodulators, such as rituximab and sirolimus, can be noninferior while reducing cost and toxicity.
• In vitiligo, cellular harvesting and JAK inhibition can achieve repigmentation, with facial areas often responding best.
• Dutasteride and finasteride do not appear to increase mood disorder risk in the available data.
• Xanthelasma may signal broader cardiovascular risk, so dermatology patients with xanthelasmas may need cardiometabolic risk management, not just cosmetic treatment.
• Overall, the presentation argues that dermatology is entering an era of more individualized, mechanism-based, and often less invasive care with better functional and safety outcomes.